1 / 49

Potpourri of Reference Lab Cases 2017 CBBS Annual Meeting

Potpourri of Reference Lab Cases 2017 CBBS Annual Meeting. Gina Leger, MSQA, MT(ASCP)SBB, CMQ/OE(ASQ) American Red Cross Southern California Region regina.leger@redcross.org. Disclosures. I have no relevant financial relationships to disclose. Objective.

meganr
Download Presentation

Potpourri of Reference Lab Cases 2017 CBBS Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Potpourri of Reference Lab Cases2017 CBBS Annual Meeting Gina Leger, MSQA, MT(ASCP)SBB, CMQ/OE(ASQ) American Red Cross Southern California Region regina.leger@redcross.org

  2. Disclosures I have no relevant financial relationships to disclose

  3. Objective • Review the findings and resolution of at least two complex or unusual cases worked up by the Immunohematology Reference Laboratory (IRL)

  4. Patient's Information • Age, gender • Race/ethnicity • Diagnosis • Pregnancy history • Transfusion history • Transplantation history • Antibody history • Medications

  5. Routine IRL Workup • ABO and Rh (phenotype 1st case) • DAT • Panels: • 5' RT, then polyethylene glycol (PEG) added, 15' 37C → anti-IgG • Ficin 37C & AGT • Additional testing: LISS; Dithiothreitol (DTT)-tr'd RBCs in LISS

  6. Ficin/ Papain DTT Possible Specificity neg pos M, N, S, s*; Ge2, Ge4; Xga; Fya, Fyb; Ch/Rg negneg Indian; JMH pos weak Cromer; Knops; Lutheran; AnWj; MER2 variable negYta pos neg Kell; LW; Dombrock pospos A, B; H; P1; Rh; Lewis; Kidd; Fy3; Diego; Scianna; Co; Ge3; Oka; I, i; P, LKE; Ata; Csa; Era; Jra; Lan; Vel*; Sda Usefulness of Enzymes & DTT *variable Modified from Reid et al. The Blood Group Antigen FactsBook, 3rded, 2012

  7. Case #1 • 76 year old Japanese female • Surgical patient  in surgery, but doing well • Dx: osteoarthritis • Hb = 13.8 g/dL, Hct= 39.7% • No transfusion record • Group AB, D+ • DAT negative • Antibody detection: 1+ gel & LISS • Autocontrol negative

  8. Case #1: IRL initial serology Group AB, R2R2, DAT neg(IgG & C3)

  9. Case #1: Ficin Panel

  10. Case #1: LISS-IgG Panel

  11. Case #1: DTT-Treated RBCs

  12. Case #1: Patient's Phenotype

  13. Case #1: Selected RBCs - Phenotype Similar

  14. Case #1 Impressions: • Reactivity in PEG-IgG similar to LISS-IgG (no enhancement) • Reactivity enhanced by enzyme pretreatment • Reactivity not destroyed by DTT pretreatment • Phenotype similar RBCs reacted the same as random RBCs  probable antibody to high prevalence antigen

  15. Case #1 Next steps: • Test selected RBCs negative for high prevalence antigens: • Not denatured by ficin or DTT • Patient was noted to be Japanese,  concentrate on phenotypes more common in Japanese

  16. Ficin/ Possible Papain DTT High Prevalence Antibody neg pos Ch/Rg; Ge2, Ge4 negneg Indian; JMH pos weak Cromer; Knops; Lutheran; AnWj; MER2 variable negYta pos neg Kell; LW; Dombrock pos posRh; Kidd; Fy3; Diego; Scianna; Co; Ge3; Oka; I, i; P, LKE; Ata; Csa; Era; Jra; Lan; Vel*; Sda Use of Enzyme- & DTT-Treated RBCs *variable Modified from Reid et al. The Blood Group Antigen FactsBook, 3rded, 2012

  17. Case #1: Selected RBCs

  18. Case #1

  19. Case #1

  20. Case #1

  21. Case #1 Conclusion: anti-Jra Surgery concluded. No units needed for transfusion.

  22. Jra • High prevalence antigen, recently raised to blood group system status  JR Blood Group System • Named after antibody producer, Rose Jacobs, not for "Junior", in 1970 • Jr(a–) phenotype is found more commonly in Japanese, Asians • Antigen fully developed at birth • Resistant to enzyme, DTT and glycine-acid EDTA treatment

  23. Anti-Jra • Anti-Jra usually IgG • Rare antibody, clinical significance not well established • 2fatal case HDFN reported (1 mother had previous massive transfusion) • Incompatible transfusions sometimes result in HTR • Difficult to obtain Jr(a–) units! • Encourage blood donation • Recruit siblings

  24. Case #2 • 82 y/o female • Diagnosis: anemia • Hb/Hct not available (done in Dr. office) • Transfused 2 years ago • Group AB, D+ • Previous anti-M (RT) + warm auto • 2 units requested for today

  25. Case #2: Initial Testing • Previous history at American Red Cross IRL • Current sample: Group AB, D+ confirmed DAT: anti-IgG 4+, anti-C3 1+, ct 0

  26. Case #2: LISS & Ficin Panels

  27. Case #2: Allogeneic Adsorption with ZZAP-Treated RBCs • Plasma adsorbed 4X with ZZAP-treated RBCs still reacting strongly with untreated RBCs; either • very high titer autoantibody or • antibody directed to antigen destroyed by ZZAP

  28. Case #2: Testing ZZAP-Adsorbed Plasma vs ZZAP-Treated RBCs

  29. Case 2 Impressions: • Reactivity in LISS-IgG and ficin-AGT consistent with previously reported warm autoantibody • Reactivity of ZZAP-adsorbed plasma not consistent with previous workup • Antibody reacted with ficin-treated RBCs, but not with ZZAP-treated RBCs,  antibody must not react with DTT-treated RBCs

  30. Case #2 Next steps: • Try adsorption with untreated RBCs to exclude presence of common alloantibodies • Identify reactivity in ZZAP-adsorbed plasma? • Test plasma with DTT-treated RBCs • Test eluate?

  31. Case #2: Adsorption of Autoantibody With Untreated RBCs in Presence of PEG No common alloantibodies underneath the autoantibody

  32. Case #2: Testing ZZAP-Adsorbed Plasma for Antibodies to DTT-Sensitive Antigens

  33. Case #2: Additional Testing With LW(a−b−) RBCs Anti-LW

  34. Case #2: Test Plasma With DTT-Treated RBCs Autoantibody in plasma reacts with DTT-treated RBCs  not anti-LW, but has broad specificity

  35. Case #2: Eluate Autoantibody in eluate not anti-LW

  36. Case #2: Conclusions • Warm autoantibody of broad specificity reactive by LISS, ficin and saline AGT and with DTT-treated RBCs • Anti-LW (presumably autoantibody) reactive by LISS AGT detected in adsorbed plasma • Previous anti-M not demonstrable • No common alloantibodies detected in PEG-adsorbed plasma • 2 group AB, D− RBCs screened with adsorbed plasma for transfusion

  37. LW Antigen • Named for Landsteiner and Wiener in 1963 who in 1940 injected rabbits with rhesus monkey RBCs  "anti-Rh" later called anti-LW • LW antigens (LWa, LWb and Lwab) are well expressed on cord D+ and D− RBCs; D− RBCs in adults have less LW than D+ RBCs • DTT destroys LW antigens, but ficin/papain and sialidase have no effect • Acquired loss of LW antigen is temporary, detected by presence of anti-LW • Very few individuals with genetically LW(a−b−) RBCs are known • The only true LW− RBCs are Rhnull phenotype

  38. Anti-LW • Typically IgG, may be IgM • Optimally reactive at 37C • No data supporting HTR • Mild HDFN due to autoanti-LWab reported • Only four examples of alloanti-LWabhave been described in LW(a−b−) individual • When LW antigens are suppressed, the anti-LWabmay mimic alloantibody & is more common than autoanti-LWa • Transfusion of D− RBCs has been successful in many cases

  39. Case #3 • 35 year old female • Adnexal mass • Hb/Hct not in chart • Race/ethnicity not in chart • No transfusion record • Group O, D+ • Solid phase 3+ on 1 of 3 RBCs, ? on 2 of 3 RBCs • No specificity on several panels

  40. Case #3: IRL Initial Testing • Group O, R1R2 • DAT negative

  41. Case #3: LISS Panel Anti-Jka reacting weakly in LISS-IgG only with double-dose Jk(a+) RBCs.

  42. Case #3: Patient's Phenotype Patient's RBCs are Jk(a−b−), Jk:−3 !

  43. Case #3: Selected RBCs

  44. Case #3: Jk(a−b−)Selected RBCs Anti-Jk3 in PEG-IgG

  45. Case #3: Conclusion • Group O, R1R2; Jk(a−b−) • Plasma: anti-Jka weakly reactive by LISS-IgG and anti-Jk3 detected by PEG-IgG • Transfusion recommendation: Group O, D+, Jk:−3

  46. Jk3 • High prevalence antigen identified in 1959 • Jk(a−b−) RBCs are Jk:−3, rare null phenotype found most commonly in Polynesians • Kidd antigens well developed at birth • Resistant to treatment with ficin, DTT and glycine acid EDTA • Jk:−3 RBCs are resistant to 2M urea lysis

  47. Anti-Jk3 • Produced by immunized Jk(a−b−) • Sometimes present with separable anti-Jka or -Jkb • Reacts equally well with Jk(a+b−), Jk(a+b+) and Jk(a−b+) RBCs • Usually IgG • Reactivity enhanced with protease-treated RBCs • Immediate & delayed HTR • Mild HDFN

  48. Review of IRL Cases: • Anti-Jra (antibody to high prevalence antigen, found predominantly in Japanese) • Autoanti-LW under broadly reactive warm autoantibody Anti-Jk3 (antibody to high prevalence antigen, found predominantly in Pacific Islanders and Asians)

More Related